# Gator SCALES-WHF: SubCutaneous Administration of Lasix to Eliminate Symptoms of Worsening Heart Failure

Study · id `cardio:ct-nct06979726` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06979726](<https://clinicaltrials.gov/study/NCT06979726>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06979726

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 100 participants.

## Technical summary

Registry record NCT06979726. Allocation not applicable; no masking; primary purpose treatment. Start 2025-11-20 (actual); primary completion 2026-11-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT06979726, source copy `cardio:ctgov-nct06979726-2026-06-08`, retrieved 2026-10-26)
- Started: 2025-11-20 (actual) (ClinicalTrials.gov record NCT06979726, source copy `cardio:ctgov-nct06979726-2026-06-08`, retrieved 2026-10-26)
- Primary completion: 2026-11-30 (anticipated) (ClinicalTrials.gov record NCT06979726, source copy `cardio:ctgov-nct06979726-2026-06-08`, retrieved 2026-10-26)
- Completion: 2026-12-31 (anticipated) (ClinicalTrials.gov record NCT06979726, source copy `cardio:ctgov-nct06979726-2026-06-08`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT06979726, source copy `cardio:ctgov-nct06979726-2026-06-08`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06979726-2026-06-08`, retrieved 2026-10-26)

## The registry's words

- Brief title: Gator SCALES-WHF: SubCutaneous Administration of Lasix to Eliminate Symptoms of Worsening Heart Failure
- Acronym: GatorScalesWHF
- Condition: Heart Failure
- Condition: Volume Overload
- Intervention (Drug): Lasix ONYU
- Lead sponsor: University of Florida
- Lead sponsor class: OTHER
- Collaborator: SQ Innovation, Inc.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry lists this organization as the lead sponsor: University of Florida (`cardio:org-university-of-florida`)

## Provenance

Content hash: 46237fc8078a090871d63793ec90c515664d541b46c1ba89b4e42db466c8dd6d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
